Rainmed Medical Ltd
02297
Company Profile
Business description
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company’s core products, the caFFR system and the caIMR system are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
Contact
No. 99, Jinji Lake Avenue
Building 31, Northeast District
Suzhou Industrial Park, Jiangsu Province
Suzhou215000
CHNT: +86 51262622215
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
270
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,212.10 | 63.00 | 0.69% |
CAC 40 | 7,923.45 | 53.11 | 0.67% |
DAX 40 | 24,359.30 | 18.20 | -0.07% |
Dow JONES (US) | 44,946.12 | 34.86 | 0.08% |
FTSE 100 | 9,138.90 | 38.34 | -0.42% |
HKSE | 25,270.07 | 249.25 | -0.98% |
NASDAQ | 21,622.98 | 87.69 | -0.40% |
Nikkei 225 | 43,378.31 | 729.05 | 1.71% |
NZX 50 Index | 12,889.38 | 55.30 | 0.43% |
S&P 500 | 6,449.80 | 18.74 | -0.29% |
S&P/ASX 200 | 8,938.60 | 64.80 | 0.73% |
SSE Composite Index | 3,696.77 | 30.33 | 0.83% |